- MyIllumina
- Tools
Single nucleotide polymorphisms (SNPs) and structural variants are at the root of genetic variation among individuals and populations. This variation influences how individuals differ in their risk of disease and their response to therapeutic treatments. SNPs and structural variants are discovered within the genome by comparing multiple genomic sequences from a diverse sample set of individuals. Illumina's industry-leading sequencing technology provides the sample throughput level and high-quality data required for accurate SNP discovery and structural variation analysis studies.
SNP Discovery and Genotyping
SNP discovery studies provide valuable allelic variation information that can be translated into content for genotyping experiments on BeadArray products. SNP discovery is at the heart of large world-wide collaborative studies like the HapMap Project and the 1000 Genomes Project, which aim to comprehensively catalog human genetic variation. The data generated by these cutting-edge studies is an important source of content for Illumina's broad portfolio of whole-genome genotyping BeadArray products. While the majority of SNP discovery studies and array-based products focus on human genetics, Illumina sequencing allows customized genotyping products to be created for any species of interest through the iSelect program.
SNP Discovery and Structural Variation Analysis
Illumina's portfolio of sequencing systems generate the highest quality data available to analyze any genome for any species, and every genetic variant. A flexible, convenient workflow allows you to combine both short-insert paired-end and long-insert mate pair libraries to create an optimal level of detail and accuracy for any study. Go rapidly from DNA to data with minimal hands-on effort to produce meaningful results, reliably and efficiently.
At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina's innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.